首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy.
【24h】

Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy.

机译:长期对基于ARA-C的化疗的长期随访,然后对成人急性淋巴细胞白血病进行骨髓移植:诱导ARA-C剂量和排放后疗法的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

We report single institution outcome of brief, intensive ara-C-based chemotherapy using bone marrow transplantation as primary intensification for untreated adult patients with acute lymphoblastic leukemia (ALL). Overall disease-free and overall survival were inferior to those reported with prolonged chemotherapy modeled on pediatric protocols. Survival and disease-free survival were superior for patients receiving allogeneic BMT compared with chemopurged autologous transplant or maintenance chemotherapy (patients ineligible for or declining BMT). In multivariate analysis, non-L2-FAB, higher ara-C dose, absence of CNS disease, non-Ph1+ karyotype, allogeneic BMT, T cell phenotype, and younger age were associated with improved disease-free survival. Autologous BMT was not superior to chemotherapy, and appears unlikely to provide adequate curative treatment for most adult ALL patients if not followed by maintenance.
机译:我们报告了使用骨髓移植作为急性淋巴细胞白血病(ALL)的未经治疗的成年患者(ALL)的初级强化(ALL)的初级强化,以简短的,密集的ARA-C基化学疗法的单一机构结局。 总体无疾病和总生存率不如报道的长期化学疗法以小儿方案进行建模的疾病。 与化学的自体移植或维持化疗相比,接受同种异体BMT的患者的生存率和无疾病生存率优越(患者不符合BMT或减少BMT)。 在多变量分析中,非L2-FAB,较高的ARA-C剂量,不存在CNS疾病,非PH1+核型,同种异体BMT,T细胞表型和年龄较小,与改善的无病生存率有关。 自体BMT并不优于化学疗法,并且如果不进行维护,似乎不可能为大多数所有患者提供足够的治疗治疗方法。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号